Vertex Pharmaceuticals Shares Gain

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis.
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
FDA approves new nonopioid pain medication, hailed a 'triumph'
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain. Vertex Pharmaceuticals’ suzetrigine, which will be marketed under the name Journavx, targets specific sodium channels that help pass signals on from the site of pain.
FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she says she experienced when taking opioids.
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company Vertex Pharmaceuticals on Thursday. The drug, which is called suzetrigine and will be sold under the brand name Journavx, is the first new type of pain medicine approved by the agency in more than 20 years.
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
FDA Approves Vertex Pharmaceuticals’ First-in-Class Non-Opioid Journavx for Moderate-to-Severe Acute Pain
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
FDA Approves First Non-Opioid Painkiller In 20+ Years: 'A Historic Milestone'
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain.Journavx received FDA approval,
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
Optimistic Outlook for Vertex Pharmaceuticals: Strong Performance, New Approvals, and Promising Pipeline Drive Buy Rating
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...